Odonate (ODTC) Stock Price

Odonate Price

OTC·CLOSED
50,000.00
​
Market closed

Odonate stock price

Access this data via the Eulerpool API

Odonate business model & stock analysis

Odonate Therapeutics, Inc. is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. The company is focused on the development of tesetaxel, a novel chemotherapy agent. The company has completed Phase-II studies in patients with metastatic breast cancer (MBC). The firm's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

Frequently asked questions about Odonate

7 analysts currently rate the Odonate stock: 0 recommend buying, 4 holding and 3 selling.

Converted at the current exchange rate, the Odonate share trades at 43,961.96 EUR (50,000.00 USD).

The Odonate share (ODTC) is listed on 5 stock exchanges, including: NASDAQ (ODT), Frankfurt (4OD.F), München (4OD.MU).

The revenue cannot currently be calculated for Odonate.

The profit cannot currently be calculated for Odonate.

The P/E ratio cannot be calculated for Odonate at the moment.

The P/S cannot be calculated for Odonate currently.

The Eulerpool Quality Score for Odonate is 1/10.

The ISIN of Odonate is US6760794031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Odonate is A2H9FC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Odonate is ODTC. The ticker symbol is used to trade Odonate shares on the stock exchange.

Fair ValueTerminal
41,000.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website odonate.com
Currency
USD
Initial public offering
Dec 7, 2017
ISIN
US6760794031
Cusip
676079106
Sedol
BD1KGM3
Market capitalization
52.65 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.63 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
272.23 USD
Net Debt / EBIT
45.59
Debt/Equity
0.02
Last updated Sep 29, 2026, 3:12 PM

Odonate Peer Group

Odonate Ticker

FRANKFURT · 4OD.FMUNICH · 4OD.MUNASDAQ · ODTOTC · ODTCOTC · ODTC

All fundamentals and in-depth analysis of Odonate

Our stock analysis for Odonate stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Odonate. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.